11/15
09:09 am
itos
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
Medium
Report
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
11/15
08:02 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
11/13
12:45 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Medium
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
11/12
07:00 am
itos
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
Low
Report
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/24
07:00 am
itos
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
Low
Report
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
9/16
08:03 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
High
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
9/15
04:02 am
itos
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT [Seeking Alpha]
High
Report
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT [Seeking Alpha]
9/14
02:37 am
itos
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients [Yahoo! Finance]
High
Report
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients [Yahoo! Finance]
9/14
02:30 am
itos
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
High
Report
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
8/28
04:30 pm
itos
iTeos to Participate in Upcoming Investor Conferences
Low
Report
iTeos to Participate in Upcoming Investor Conferences
8/25
09:36 am
itos
We're Keeping An Eye On iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate [Yahoo! Finance]
Low
Report
We're Keeping An Eye On iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate [Yahoo! Finance]